2019 logo_150x35_jpg.jpg
EPI Health, a Novan Company, and MC2 Therapeutics Present WYNZORA® (calcipotriene and betamethasone dipropionate) Cream, 0.005%/0.064% Subgroup Data Analysis at Skin of Color Update 2022 Conference
September 15, 2022 08:00 ET | Novan, Inc.
– New data analysis from previously completed successful Phase 3 study1 demonstrated WYNZORA® Cream to be effective and convenient for skin of color patients for the treatment of plaque psoriasis ...
2019 logo_150x35_jpg.jpg
Novan Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 11, 2022 06:30 ET | Novan, Inc.
– Total revenue of $6.2 million for the second quarter 2022 – – Activities on track for submission of berdazimer gel, 10.3% (SB206) New Drug Application (NDA), targeting submission before the...
2019 logo_150x35_jpg.jpg
Novan to Report Second Quarter 2022 Financial Results on August 11, 2022
August 04, 2022 09:05 ET | Novan, Inc.
DURHAM, N.C., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its second quarter 2022 financial results on Thursday,...
2019 logo_150x35_jpg.jpg
Novan Satisfies $16.5 Million Outstanding Promissory Note
July 19, 2022 08:30 ET | Novan, Inc.
– Novan and Evening Post Group enter into a loan payoff and termination agreement, fully satisfying the promissory note and all related obligations – – Novan saves $11.1 million in principal and...
2019 logo_150x35_jpg.jpg
Novan Announces Closing of Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 13, 2022 16:05 ET | Novan, Inc.
DURHAM, N.C., June 13, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced the closing of the Company’s previously announced registered direct offering...
2019 logo_150x35_jpg.jpg
Novan Announces Approximately $15.0 Million Registered Direct Offering Priced At-the-Market
June 09, 2022 08:30 ET | Novan, Inc.
DURHAM, N.C., June 09, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it has entered into a definitive agreement with an institutional investor to...
2019 logo_150x35_jpg.jpg
Novan to Present Berdazimer Gel, 10.3% (SB206) Clinical Data at Annual Meeting of the Society for Investigative Dermatology
May 19, 2022 09:05 ET | Novan, Inc.
– Based on clinical data from previously completed B-SIMPLE4 pivotal Phase 3 clinical study, berdazimer gel, 10.3% (SB206) can shorten the duration of molluscum infection and increase the chance of...
2019 logo_150x35_jpg.jpg
Novan Reports First Quarter 2022 Financial Results and Provides Corporate Update
May 16, 2022 06:30 ET | Novan, Inc.
– Transformational quarter for Novan, marked by acquisition of EPI Health – – Strongest quarter in total prescriptions for Rhofade increasing 47% from Q1 2021 – – Ongoing activities toward...
2019 logo_150x35_jpg.jpg
Novan to Report First Quarter 2022 Financial Results on May 16, 2022
May 06, 2022 09:00 ET | Novan, Inc.
DURHAM, N.C., May 06, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced that it will report its first quarter 2022 financial results on Monday, May...
2019 logo_150x35_jpg.jpg
Novan to Participate in the Virtual Investor Innovation in Dermatology Spotlight Event
April 20, 2022 09:05 ET | Novan, Inc.
DURHAM, N.C., April 20, 2022 (GLOBE NEWSWIRE) -- Novan, Inc. (“the Company” or “Novan”) (Nasdaq: NOVN), today announced it will participate in the Virtual Investor Innovation in Dermatology...